Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (31-40 of 616) with videos related to

Pageof 62
Sort By:
Hepatology (Baltimore, Md.)|March 5, 2014
Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Hepatology International|August 8, 2024
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLDChun-Jen Liu, Wai Kay Seto, Ming-Lung Yu
Hepatology (Baltimore, Md.)|April 5, 2013
Pegylated interferon and ribavirin: a therapeutic option in patients who fail to respond to telaprevir-based triple therapy?Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Expert Review of Anti-Infective Therapy|January 11, 2021
Elbasvir and grazoprevir for the treatment of hepatitis CSzu-Jen Wang, Chung-Feng Huang, Ming-Lung Yu
JAMA Network Open|September 13, 2022
Simulation of Long-term Outcomes in Patients With Nonalcoholic Fatty Liver DiseaseJee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang
Hepatology International|March 1, 2022
Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?George Lau, Ming-Lung Yu, Grace Wong, et al.
Expert Opinion on Drug Safety|May 5, 2017
Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individualsJacinta A Holmes, Ming-Lung Yu, Raymond T Chung
The Kaohsiung Journal of Medical Sciences|January 3, 2012
Chronic hepatitis C infection in the elderlyChung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu
Kidney International|January 26, 2020
Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patientsChung-Feng Huang, Yi-Wen Chiu, Ming-Lung Yu
Alimentary Pharmacology & Therapeutics|February 6, 2026
Editorial: Beyond Viral Eradication-Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' ReplyPei-Chien Tsai, Jee-Fu Huang, Ming-Lung Yu
Pageof 62

Showing results (31-40 of 616) with videos related to

Sort By:
Pageof 62
Hepatology (Baltimore, Md.)|March 5, 2014
Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Hepatology International|August 8, 2024
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLDChun-Jen Liu, Wai Kay Seto, Ming-Lung Yu
Hepatology (Baltimore, Md.)|April 5, 2013
Pegylated interferon and ribavirin: a therapeutic option in patients who fail to respond to telaprevir-based triple therapy?Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Expert Review of Anti-Infective Therapy|January 11, 2021
Elbasvir and grazoprevir for the treatment of hepatitis CSzu-Jen Wang, Chung-Feng Huang, Ming-Lung Yu
JAMA Network Open|September 13, 2022
Simulation of Long-term Outcomes in Patients With Nonalcoholic Fatty Liver DiseaseJee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang
Hepatology International|March 1, 2022
Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?George Lau, Ming-Lung Yu, Grace Wong, et al.
Expert Opinion on Drug Safety|May 5, 2017
Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individualsJacinta A Holmes, Ming-Lung Yu, Raymond T Chung
The Kaohsiung Journal of Medical Sciences|January 3, 2012
Chronic hepatitis C infection in the elderlyChung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu
Kidney International|January 26, 2020
Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patientsChung-Feng Huang, Yi-Wen Chiu, Ming-Lung Yu
Alimentary Pharmacology & Therapeutics|February 6, 2026
Editorial: Beyond Viral Eradication-Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' ReplyPei-Chien Tsai, Jee-Fu Huang, Ming-Lung Yu
Pageof 62